Print

Clovis Oncology (CLVS) Shares Drop As Analysts Give Edge To Lung-Cancer Rival  
6/4/2014 7:05:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

It was an American Society of Clinical Oncology meeting to remember for Clovis Oncology, but not in a good way. The sudden fall of the Boulder-based drug company’s stock price was one of the most prominent stories to emerge from the conference, which was held in Chicago over the weekend. Clovis’s (NASDAQ: CLVS) share price fell more than 25 percent the past two days, dropping to $38.23 per share at market close Tuesday after ending last week at $51.21 per share.

Help employers find you! Check out all the jobs and post your resume.

//-->